In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
13 authors.
Alexander A CohenDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.ORCID 0000-0002-2818-656X Jennifer R KeeffeDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.ORCID 0000-0002-5317-6398 Lusineh ManasyanDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Indeever MadireddyDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.ORCID 0000-0002-8460-8579 Ange-Célia I Priso FilsDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.ORCID 0009-0001-3506-1079 Haley E StoberGladstone Institutes, San Francisco, CA 94158, USA.
Rory A HillsDepartment of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1PD, UK.ORCID 0000-0002-5698-9538 Paulo J C LinAcuitas Therapeutics, Vancouver, BC, V6T 1Z3, Canada.
Mark R HowarthDepartment of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1PD, UK.ORCID 0000-0001-8870-7147 Pamela J BjorkmanDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.ORCID 0000-0002-2277-3990 Funding
The longevity and nature of the anti-SARS-CoV-2 cellular and humoral immune responsesP01AI165075 · NIAID · ROCKEFELLER UNIVERSITY · PI BJORKMAN, PAMELA J · 2022 to 2023
$10.7MSelf-Assembling Spike-EBR Nanoparticles as a Vaccine Platform Technology Against SARS-CoV-2 and Future Pandemic Coronaviruses.DP5OD033362 · OD · J. DAVID GLADSTONE INSTITUTES · PI HOFFMANN, MAGNUS ADRIAN GERO · 2022 to 2025
$2.3MDetermining the role of antibody epitope specificity in regulating Fc effector functionsK99AI185267 · NIAID · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI Alexander A Cohen · 2025 to 2026
$257kNIAID NIH HHS K99 AI185267NIAID NIH HHS P01 AI165075NIH HHS DP5 OD033362Wellcome Trust
6 · The paper itselfAbstract
Global health remains threatened by spillovers of zoonotic SARS-like betacoronaviruses (sarbecoviruses) that could be mitigated by a pan-sarbecovirus vaccine
Indexed as
Deep mutational scanningepitope mappingmRNA and protein nanoparticle vaccinespandemic preparednesspan-sarbecovirus vaccineSySPEM (systems serology-polyclonal epitope mapping)systems serology
Identifiers
PMID41280075
PMCPMC12633426
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390